##### Table of Contents



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, DC 20549
 FORM 10-Q
 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
 For the quarterly period ended: July 2, 2006
 Commission file number: 1-10827
 PAR PHARMACEUTICAL COMPANIES, INC.
  Delaware
    
    22-3122182(State or other jurisdiction of
incorporation or organization)
    
    (I.R.S. Employer
Identification No.)300 Tice Boulevard,
Woodcliff Lake, New Jersey
(Address of principal executive offices)
    
    07677
(Zip Code)
   þ o
  þ o o
  o þ




---



##### 



TABLE OF CONTENTS
PAR PHARMACEUTICAL COMPANIES, INC.
FORM 10-Q
FOR THE FISCAL QUARTER ENDED JULY 2, 2006:
 PAGESPART I FINANCIAL INFORMATIONItem 1. Financial Statements
    
    2Item 2. Managements Discussion and Analysis of Financial
Condition and Results of Operations
    
    2Item 3. Quantitative and Qualitative Disclosures about Market Risk
    
    2Item 4. Controls and Procedures
    
    4PART II OTHER INFORMATIONItem 1. Legal Proceedings
    
    4Item 1A. Risk Factors
    
    4Item 4. Submission of Matters to a Vote of Security Holders
    
    6Item 6. Exhibits
    
    7SIGNATURES
    
    8Certification of the Principal Executive OfficerCertification of the Principal Financial OfficerCertification of the President and cheif Executive Officer pursuant to Section 906Certification of the Chief Financial Officer pursuant to Section 906




---



##### Table of Contents



PART I  FINANCIAL INFORMATION
   
 Item 1. Financial Statements
 As previously disclosed on the Registrants Form 8-K filed on July 6, 2006, due to accounting
errors, certain financial information of the Registrant for the fiscal years ended December 31,
2004 and December 31, 2005, and for the quarter ended April 2, 2006, will need to be restated and
should no longer be relied upon. Due to the work involved in restating the affected financial
statements, which has not been completed, the Registrant is presently unable to file Part I, Item 1
to its Quarterly Report on Form 10-Q for the quarter ended July 2, 2006. The Registrant is working
diligently to review and finalize the information subject to the Restatement and intends to amend
this Quarterly Report on Form 10-Q for the quarter ended July 2, 2006 to include the information
required by Part I, Item 1 as soon as practicable. Accordingly, this Report is qualified in its
entirety by the absence of such information. Please see the Registrants Notification of Late
Filing on Form 12b-25 filed with the Commission as of the date hereof for more details.
 
 Item 2. ManagementS Discussion and Analysis of Financial Condition and Results of
Operations
 As previously disclosed on the Registrants Form 8-K filed on July 6, 2006, due to accounting
errors, certain financial information of the Registrant for the fiscal years ended December 31,
2004 and December 31, 2005, and for the quarter ended April 2, 2006, will need to be restated and
should no longer be relied upon. Due to the work involved in restating the affected financial
statements, which has not been completed, the Registrant is presently unable to file Part I, Item 2
to its Quarterly Report on Form 10-Q for the quarter ended July 2, 2006. The Registrant is working
diligently to review and finalize the information subject to the Restatement and intends to amend
this Quarterly Report on Form 10-Q for the quarter ended July 2, 2006 to include the information
required by Part I, Item 2 as soon as practicable. Accordingly, this Report is qualified in its
entirety by the absence of such information. Please see the Registrants Notification of Late
Filing on Form 12b-25 filed with the Commission as of the date hereof for more details.
 
 Item 3. Quantitative and Qualitative Disclosures About Market Risk
   July 2,
    
    
    Dec. 31,2006
    
    
    2005Securities issued by U.S. government and agencies
    
    $
    76,767
    
    
    $
    79,886Debt securities issued by various state and local
municipalities and agencies
    
    
    11,668
    
    
    
    13,721Other marketable debt securities
    
    
    13,792
    
    
    
    13,200Total
    
    $
    102,227
    
    
    $
    106,807
 2




---



##### Table of Contents



Available for Sale Securities:
    ®
  3




---



##### Table of Contents



Item 4. Controls and Procedures
  
 PART II. OTHER INFORMATION
 
 Item 1. Legal Proceedings
   Contractual Matters
 Ò
 4




---



##### Table of Contents



Patent Related Matters
    5




---



##### Table of Contents



Ò
  ®
 6




---



##### Table of Contents



Industry Related Matters
   7




---



##### Table of Contents



8




---



##### Table of Contents



Item 1a. Risk Factors
  Risks that Relate to the Registrants Accounting and Internal Controls
 The Registrant must restate its financial statements for the years ended December 31, 2004 and
December 31, 2005, and its quarter ended April 2, 2006, and investors should not rely on such prior
financial statements until they are restated and filed with the Commission.
    9




---



##### Table of Contents









The Registrant likely has material weaknesses in its internal control over financial reporting.


significant deficiency material weakness




As a result of the required restatement, material information concerning the Registrants 2004
through the second quarter of 2006 operating results and financial condition is not available and
is not expected to be available at any certain time.




The Registrant may lose existing customers or may not be successful in gaining new customers or
commercial relationships as a result of the issues relating to the restatement of the Prior
Financial Statements, its internal controls and related matters.


10




---



##### Table of Contents










Item 4. Submission of Matters to a Vote of Security Holders




Proposal I




VOTES FOR
    
    WITHHELDPeter S. Knight
    
    
    28,125,524
    
    
    
    2,505,017L. William Seidman
    
    
    28,105,600
    
    
    
    2,524,941Scott Tarriff
    
    
    28,600,407
    
    
    
    2,030,134


Proposal
II







Item 6. Exhibits


31.1
    
    Certification of the Principal Executive Officer.31.2
    
    Certification of the Principal Financial Officer.32.1
    
    Certification by the Chief Executive Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.32.2
    
    Certification by the Chief Financial Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.


11



---



##### Table of Contents



SIGNATURES
  PAR PHARMACEUTICAL COMPANIES, INC.
(Registrant)Date: August 11, 2006
    
    /s/ Scott TarriffScott TarriffPresident and Chief Executive OfficerDate: August 11, 2006
    
    /s/ Gerard A. Martino

Gerard A. MartinoExecutive Vice President and Chief Financial Officer
 12




---



##### Table of Contents



EXHIBIT INDEX
 Exhibit Number
    
    Description31.1
    
    Certification of the Principal Executive Officer pursuant
to Rule 13a-14(a) of the Exchange Act.31.2
    
    Certification of the Principal Financial Officer pursuant
to Rule 13a-14(a) of the Exchange Act.32.1
    
    Certification by the President and Chief Executive Officer
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.32.2
    
    Certification by the Chief Financial Officer pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002.
 13